Arcturus Therapeutics Holdings Inc.
NASDAQ:ARCTBiotechnology
+$0.15 today
- Market cap
- $231.73M
- Beta
- 2.35
- P/E (TTM)
- -2.7
- EPS (TTM)
- -$2.77
Volume 0.64M
Average 0.43M
ARCT Net Margin
Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.
Arcturus Therapeutics Holdings Inc.NASDAQ: ARCT
Net Margin · Q1 FY2026 · quarter ended Mar 2026
Net margin narrows to -4420.3%
Net margin was -4420.3% in Q1 FY2026, down 4372.4 pp from a year earlier. On a trailing-twelve-month basis it was -173.5%, down 123.0 pp year over year. Over 3 fiscal years it narrowed by 102.4 pp.
Context
- Net margin widened in 0 of the last 3 fiscal years.
- FY2025 was the lowest level in the 4 fiscal years shown.
What to watch
Whether net margin reaches the consensus estimate from 8 analysts of -322.5% for the fiscal year ending Dec 2026, down from -97.9% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -4420.3%-3476.5 pp QoQ
- Last fiscal yearDec 2025
- -97.9%-39.4 pp YoY
- LTMMar 2026
- -173.5%-123.0 pp YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -97.9%
- Year-over-year change
- -39.4pp
| Period | Period end | Net Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -97.9% | -39.4pp |
| FY2024 | 2024-12-31 | -58.5% | -39.6pp |
| FY2023 | 2023-12-31 | -18.8% | -23.4pp |
| FY2022 | 2022-12-31 | 4.5% | +1652.5pp |
| FY2021 | 2021-12-31 | -1648.0% | — |
Net Margin vs competitors
How ARCT compares with its peers on the latest reported figures
- ARCT's LTM Mar 2026 net margin of -173.5% is the 4th highest of the 8 companies compared; the peer median is -339.4%.
- Its year-over-year change of -123.0 pp is the 5th highest of 7, against a peer median of -49.0 pp.
- Over three fiscal years its change of -102.4 pp compares with a peer median of -59.9 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 84.0% | +1279.8 pp | -59.9 pp | |
| LTM Mar 2026 | -14.7% | -52.9 pp | +80.3 pp | |
| LTM Mar 2026 | -88.3% | -45.1 pp | -26.3 pp | |
| LTM Mar 2026 | -173.5% | -123.0 pp | -102.4 pp | |
| LTM Mar 2026 | -339.4% | -180.3 pp | +1527.3 pp | |
| LTM Mar 2026 | -676.0% | +2093.1 pp | -670.8 pp | |
| LTM Mar 2026 | -9243.0% | — | -15619.4 pp | |
| FY2025 | -130000.0% | -80745.7 pp | -127273.3 pp | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding ARCT) | -339.4% | -49.0 pp | -59.9 pp | |
Competitors are the stored peer set for ARCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 12.36M | 205.76M | 157.75M | 138.39M | 67.22M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 3.03M |
| Gross Profit | 12.36M | 205.76M | 157.75M | 138.39M | 64.2M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 95.5% |
| Research & Development | 173.76M | 147.75M | 192.13M | 195.16M | 112.21M |
| Selling, General & Admin | 41.45M | 46.07M | 52.87M | 52.82M | 46.08M |
| Operating Expenses | 215.21M | 193.58M | 235.95M | 234.06M | 139.15M |
| Depreciation & Amortization | 1.19M | 1.53M | 2.96M | 3.54M | 3.03M |
| EBITDA | (199.81M) | 15.17M | (24.17M) | (77.4M) | (62.76M) |
| EBITDA Margin | -1616.7% | 7.4% | -15.3% | -55.9% | -93.4% |
| Operating Income | (202.85M) | 12.18M | (78.21M) | (95.67M) | (74.96M) |
| Operating Margin | -1641.3% | 5.9% | -49.6% | -69.1% | -111.5% |
| Interest Income | 753K | 2.58M | 17.36M | 15.2M | 10.1M |
| Interest Expense | 2.67M | 3M | 767K | 0 | 0 |
| Other Income / Expenses | (822K) | (1.53M) | 50.32M | 14.72M | 9.17M |
| Income Before Tax | (203.67M) | 10.64M | (27.89M) | (80.95M) | (65.78M) |
| Pre-Tax Margin | -1648.0% | 5.2% | -17.7% | -58.5% | -97.9% |
| Income Tax Expense | 0 | 1.3M | 1.84M | (4K) | 0 |
| Net Income | (203.67M) | 9.35M | (29.73M) | (80.94M) | (65.78M) |
| Net Margin | -1648.0% | 4.5% | -18.8% | -58.5% | -97.9% |
| EPS (Basic) | (7.74) | 0.35 | (1.12) | (3.00) | (2.40) |
| EPS (Diluted) | (7.74) | 0.35 | (1.12) | (3.00) | (2.40) |
| Weighted Avg Shares | 26.32M | 26.45M | 26.63M | 27M | 27.39M |
| Weighted Avg Shares (Diluted) | 26.32M | 27.09M | 26.63M | 27M | 27.39M |
Arcturus Therapeutics Holdings Inc.
NASDAQ:ARCT
Intrinsic Alpha fair value
Locked
Current Price
$8.04
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.